HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy.

Abstract
Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome caused by germline mutations in the VHL tumor-suppressor gene. Central nervous system (CNS) and retinal hemangioblastomas are highly vascular tumors that are hallmarks of the disease. These tumors overexpress vascular endothelial growth factor (VEGF) and represent a potential target for anti-angiogenic drugs. We observed, after 3 to 4 months of treatment, secondary paradoxical polycythemia in 3 VHL patients with CNS or retinal hemangioblastomas treated by the anti-VEGF receptor SU5416. Hematocrit was normal before the beginning of the trial, and no progression of hemangioblastomas was observed. Polycythemia vera and all known causes of secondary polycythemia were also ruled out. Polycythemia has never been reported in current SU5416 trials for advanced malignancies and could express a specific action on red blood cell precursors occurring only in the absence of a functional VHL gene. These findings could also affect the inclusion of VHL patients with pre-existing polycythemia in future anti-VEGF receptor trials.
AuthorsStéphane Richard, Laure Croisille, Jeannine Yvart, Nicole Casadeval, Pascal Eschwège, Nozar Aghakhani, Philippe David, Alain Gaudric, Paul Scigalla, Olivier Hermine
JournalBlood (Blood) Vol. 99 Issue 10 Pg. 3851-3 (May 15 2002) ISSN: 0006-4971 [Print] United States
PMID11986247 (Publication Type: Case Reports, Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Enzyme Inhibitors
  • Indoles
  • Pyrroles
  • Receptors, Growth Factor
  • Semaxinib
  • Receptor Protein-Tyrosine Kinases
  • Receptors, Vascular Endothelial Growth Factor
Topics
  • Adult
  • Angiogenesis Inhibitors (adverse effects)
  • Enzyme Inhibitors (adverse effects)
  • Female
  • Hematocrit
  • Humans
  • Indoles (adverse effects)
  • Kinetics
  • Male
  • Middle Aged
  • Polycythemia (diagnosis, etiology)
  • Pyrroles (adverse effects)
  • Receptor Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Receptors, Growth Factor (antagonists & inhibitors)
  • Receptors, Vascular Endothelial Growth Factor
  • von Hippel-Lindau Disease (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: